person · Reporting owner

Choi Jung

Disclosed activity across 2 companies

Tapewire entity: 38057
SEC CIK: 0001650126

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Annexon, Inc.ANNX · Entity 5011	Director	June 11, 2026	June 15, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Annexon, Inc.

Report date June 11, 2026 · Filed June 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11	Direct	65,000	Reported balance After 2026-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Global Blood Therapeutics, Inc.

Report date October 05, 2022 · Filed October 06, 2022

Section 16 reporting ended · disclosed 2022-10-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-10-05 transaction · row 1 1 source row Row 1 · 2022-10-05 · Disposition to issuer · Disposed 226,672 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Common StockSEC Table I · non-derivative	IndirectBy Trust	Reported balance After 2022-10-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2022-10-05 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement. F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-10-05 · Disposition to issuer · Disposed 3,125 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-10-05 · Disposition to issuer · Disposed 9,060 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-10-05 · Disposition to issuer · Disposed 13,814 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-10-05 · Disposition to issuer · Disposed 15,460 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-10-05 · Disposition to issuer · Disposed 26,454 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2022-10-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-10-05 · Disposition to issuer · Disposed 42,400 · Balance 0 F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock. F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40	Direct	Reported balance After 2022-10-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40	Direct	Reported balance After 2022-10-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-10-05 · Disposition to issuer · Disposed 1 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.40	Direct	Reported balance After 2022-10-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-10-05 · Disposition to issuer · Disposed 32,098 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.60	Direct	Reported balance After 2022-10-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-10-05 · Disposition to issuer · Disposed 35,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.44	Direct	Reported balance After 2022-10-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-10-05 · Disposition to issuer · Disposed 40,000 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.82	Direct	Reported balance After 2022-10-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-10-05 · Disposition to issuer · Disposed 36,225 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.48	Direct	Reported balance After 2022-10-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2022-10-05 · Disposition to issuer · Disposed 38,739 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.87	Direct	Reported balance After 2022-10-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2022-10-05 · Disposition to issuer · Disposed 28,628 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the "Merger"), effective as of the effective time of the Merger (the "Effective Time") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the "Merger Consideration"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement.

F2: (Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.

F3: Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements ("RSU") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements ("PSU") represented a contingent right to receive one share of Common Stock.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU, was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence.

F6: Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time.

F7: Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an "Issuer Stock Option"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 01, 2019 Filed Aug 5, 2019 17:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	10,062	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-021018 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
July 31, 2019 Filed Aug 5, 2019 17:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	285	$36.68	$10,453.80	Disclosure SEC source: 0000899243-19-021018 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,136 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
April 08, 2019 Filed Apr 10, 2019 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-010472 · doc4.xml · derivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On April 8, 2019, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On April 8, 2019, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
April 08, 2019 Filed Apr 10, 2019 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	692	$58.51	$40,488.92	Disclosure SEC source: 0000899243-19-010472 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,851 F3 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,000 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
April 08, 2019 Filed Apr 10, 2019 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	2,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-010472 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,875	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 2,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F6 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2018, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,063	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · derivative · entry 6 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,250 Underlying: Common Stock · 4,063 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F5 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2017, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantRestricted Stock Units · Derivative	25,000	$0.00	$0.00	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · derivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $48.44	$0.00	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · derivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2029-01-31 F3 · derivative.exercise_date: The shares of Common Stock underlying the option vest in 16 equal quarterly installments over 4 years from February 1, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	2,515	$48.44	$121,826.60	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,997 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 6,938 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
February 01, 2019 Filed Feb 5, 2019 17:53 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	6,938	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-19-002668 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
January 31, 2019 Filed Apr 10, 2019 16:15 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	269	$36.68	$9,866.92	Disclosure SEC source: 0000899243-19-010472 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,543 F1 · shares: Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:51 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,875	$0.00	$0.00	Disclosure SEC source: 0000899243-18-021421 · doc4.xml · derivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,125 Underlying: Common Stock · 2,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. F4 · derivative.expiration_date: The RSUs vest in eight equal semi-annual installments after February 1, 2018 until fully vested on February 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:51 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	4,062	$0.00	$0.00	Disclosure SEC source: 0000899243-18-021421 · doc4.xml · derivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,313 Underlying: Common Stock · 4,062 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in eight equal semi-annual installments after February 1, 2017 until fully vested on February 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. F3 · derivative.expiration_date: The RSUs vest in eight equal semi-annual installments after February 1, 2017 until fully vested on February 1, 2021, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason upon a change of control of the Issuer. Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:51 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Tax withholdingCommon Stock	3,440	$43.15	$148,436.00	Disclosure SEC source: 0000899243-18-021421 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,574 F2 · shares: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 3,250 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document
August 01, 2018 Filed Aug 3, 2018 17:51 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	6,937	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-021421 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock. Read SEC document
July 31, 2018 Filed Feb 14, 2019 17:26 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	GrantCommon Stock	277	$35.53	$9,841.81	Disclosure SEC source: 0000899243-19-003656 · doc5.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,274 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,675 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,675 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	198	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,964 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,400	$48.25	$67,550.00	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,077 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	198	$3.40	$673.20	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2018 Filed May 21, 2018 16:36 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,600	$48.25	$77,200.00	Disclosure SEC source: 0000899243-18-013572 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,077 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,276 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,276 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	198	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,162 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,400	$45.50	$63,700.00	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,677 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,077 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,476 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	198	$3.40	$673.20	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 17, 2018 Filed Apr 19, 2018 16:05 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,600	$45.50	$72,800.00	Disclosure SEC source: 0000899243-18-010408 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,677 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,877 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,877 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	198	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,360 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,400	$54.15	$75,810.00	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,277 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,677 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,076 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	198	$3.40	$673.20	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2018 Filed Mar 20, 2018 17:30 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,600	$54.15	$86,640.00	Disclosure SEC source: 0000899243-18-008156 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,277 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · derivative · entry 9 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,478 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	601	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · derivative · entry 8 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,478 Underlying: Common Stock · 601 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionStock Option (Right to Buy) · Derivative	198	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · derivative · entry 7 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,558 Underlying: Common Stock · 198 shares Expires 2025-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,400	$62.95	$88,130.00	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · nonDerivative · entry 5 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,877 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · nonDerivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	601	$3.40	$2,043.40	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · nonDerivative · entry 3 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionCommon Stock	198	$3.40	$673.20	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · nonDerivative · entry 2 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 16, 2018 Filed Feb 21, 2018 18:10 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	SaleCommon Stock	1,600	$62.95	$100,720.00	Disclosure SEC source: 0000899243-18-004892 · doc4.xml · nonDerivative · entry 1 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,877 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · shares: These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. Read SEC document
February 14, 2018 Filed Feb 16, 2018 19:16 UTC	Global Blood Therapeutics, Inc. GBT · Entity 123220	Exercise / conversionRestricted Stock Units · Derivative	2,000	$0.00	$0.00	Disclosure SEC source: 0000899243-18-004454 · doc4.xml · derivative · entry 4 Choi Jung · CIK 0001650126 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 2,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F4 · derivative.exercise_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. F4 · derivative.expiration_date: On August 11, 2017, the Reporting Person was granted 15,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 2,000 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.